Trial Profile
A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 07 Jul 2015 Results published in the British Journal of Cancer.
- 31 Aug 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Jul 2008 New trial record.